Q4 Rundown: Integral Ad Science (NASDAQ:IAS) Vs Other Advertising Software Stocks
Integral Diagnostics Director Increases Shareholding
Investors Shouldn't Be Too Comfortable With Integral Diagnostics' (ASX:IDX) Earnings
Integral Ad Science Price Target Raised to $13.50 From $13 at Morgan Stanley
Loop Capital Markets Keeps Their Buy Rating on Integral Ad Science (IAS)
Integral Ad Science Is Maintained at Buy by Truist Securities
Integral Ad Science Price Target Raised to $17.00/Share From $16.00 by Truist Securities
Express News | Scotiabank Maintains Sector Perform on Integral Ad Science, Raises Price Target to $12
Integral Ad Science Analyst Ratings
Integral Ad Science (IAS) Gets a Buy From Craig-Hallum
Integral Health Network of Southern Arizona and Banner - University Family Care Achieve 12.1% Reduction in 2023 Medical Loss Ratio
Integral Metals Advances Woods Creek Exploration With Additional Geochemical and Mineralogical Analysis
Cautious Outlook for Integral Ad Science Amid Growth Variability and Market Challenges
Analysts Offer Insights on Communication Services Companies: Integral Ad Science (IAS), Liberty Media Liberty Formula One (FWONK) and Cable ONE (CABO)
Integral Ad Science: Strong Financial Performance and Strategic Positioning Drive Buy Rating
Don't Buy Integral Diagnostics Limited (ASX:IDX) For Its Next Dividend Without Doing These Checks
Integral Ad Science Holding Full Year 2024 Earnings: EPS Misses Expectations
Integral Ad Science Reports Strong Growth and Expansion
Truist Securities Adjusts Integral Ad Science Holding Price Target to $17 From $16, Maintains Buy Rating
Earnings Call Summary | Integral Ad Science(IAS.US) Q4 2024 Earnings Conference